Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

Rheumatology (United Kingdom)

Volumn 54, Issue 7, 2015, Pages 1200-1209

  González Álvaro, Isidoro ^a   Martínez Fernández, Carmen ^b   Dorantes Calderón, Benito ^c   García Vicuña, Rosario ^a   Hernández Cruz, Blanca ^d   Herrero Ambrosio, Alicia ^e   Ibarra Barrueta, Olatz ^f   Martín Mola, Emilio ^e   Monte Boquet, Emilio ^g   Morell Baladrón, Alberto ^a   Sanmartí, Raimon ^h   Sanz Sanz, Jesús ⁱ   De Toro Santos, Francisco Javier ^j   Vela, Paloma ^k   Ivorra, José Andrés Román ^g   Poveda Andrés, José Luis ^g   Muñoz Fernández, Santiago ^l  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Epidemiol Unit Spanish Soc Rheumatol   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL DE GALDAKAO   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

more..

Author keywords

Ankylosing spondylitis; BDMARD; Biologics; CDMARD; Dose reduction; Optimization; Psoriatic arthritis; Rheumatoid arthritis; Risk benefit ratio

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; CONSENSUS; DELPHI STUDY; DRUG DOSE REDUCTION; DRUG MONITORING; E-MAIL; FOLLOW UP; HEALTH PRACTITIONER; HOSPITAL PHARMACY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; JOB EXPERIENCE; MEDICAL SOCIETY; NURSE; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SYSTEMATIC REVIEW (TOPIC); TELECONSULTATION; TREATMENT WITHDRAWAL;

EID: 84936889378     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu461     Document Type: Article

References (96)

1. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001;60:1040-5.
3. O'Neill T, Silman AJ. Psoriatic arthritis. Historical background and epidemiology. Baillieres Clin Rheumatol 1994; 8:245-61.
4. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
5. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S16-22.
6. Carmona L, Gonzalez-Alvaro I, Balsa A et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003;62:897-900.
7. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
8. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
9. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26: S35-61.
10. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
11. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5.
12. Ariza-Ariza R, Hernandez-Cruz B, Collantes E et al. Work disability in patients with ankylosing spondylitis. J Rheumatol 2009;36:2512-6.
13. Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70.
14. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2): ii14-7.
15. Pincus T, Callahan LF, Sale WG et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
16. Descalzo MA, Carbonell J, Gonzalez-Alvaro I et al. Effectiveness of a clinical practice intervention in early rheumatoid arthritis. Arthritis Care Res 2012;64: 321-30.
17. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
18. Gremese E, Salaffi F, Bosello SL et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013;72: 858-62.
19. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
20. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
21. Nell VP, Machold KP, Eberl G et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
22. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
23. Sieper J, Braun J. How important is early therapy in axial spondyloarthritis? Rheum Dis Clin North Am 2012;38: 635-42.
24. Verstappen SM, Jacobs JW, van der Veen MJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
25. Machado MADA, Barbosa MM, Almeida AM et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 2013;33:2199-213.
26. Singh JA, Christensen R, Wells GA et al. A network metaanalysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181:787-96.
27. Ash Z, Gaujoux-Viala C, Gossec L et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71: 319-26.
28. Carmona L, Descalzo MA, Perez-Pampin E et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880-5.
29. Garcia-Doval I, Perez-Zafrilla B, Descalzo MA et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69:1751-5.
30. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter activesurveillance report. Arthritis Rheum 2003;48:2122-7.
31. Pena-Sagredo JL, Farinas MC, Perez-Zafrilla B et al. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin Exp Rheumatol 2009;27:920-5.
32. Pena-Sagredo JL, Hernandez MV, Fernandez-Llanio N et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008;26:854-9.
33. Perez-Sola MJ, Torre-Cisneros J, Perez-Zafrilla B et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, aetiology and mortality in the BIOBADASER registry. Med Clin (Barc) 2011;137:533-40.
34. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72.
35. Gomez Reino J, Loza E, Andreu JL et al. [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients]. Reumatol Clin 2011;7:284-98.
36. Martínez-Pérez R, Rodríguez-Montero S, Muñoz A et al. Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis. J Transl Med 2011;9:P44.
37. Navarro-Compan V, Moreira V, Ariza-Ariza R et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011;30:993-6.
38. Escudero-Vilaplana V, Ramirez-Herraiz E, Trovato-Lopez N et al. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis. J Pharm Pharm Sci 2012;15:355-60.
39. Ramirez-Herraiz E, Escudero-Vilaplana V, Alanon-Plaza E et al. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol 2013;31:559-65.
40. Ramírez Herráiz E, Escudero Villaplana V, Alañón Plaza E et al. Uso real de antagonistas del TNF en la práctica clínica: Optimización de dosis y costes asociados en pacientes con Espondilitis Anquilosante en 2 hospitales generales universitarios. Reumatol Clin 2013;9: 26-7.
41. Maneiro JR, Perez-Pampin E, Salgado E, Carmona L, Gomez-Reino JJ. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. Rheumatol Int 2014;37:1059-63.
42. Inciarte-Mundo J, Hernandez MV, Rosario V et al. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions. Reumatol Clin 2013;10:10-6.
43. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73: 492-509.
44. Isvy A, Meunier M, Gobeaux-Chenevier C et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine 2012;79:365-9.
45. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
46. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
47. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
48. Genovese MC, Cohen S, Moreland L et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412-9.
49. Dixon WG, Abrahamowicz M, Beauchamp ME et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128-33.
50. Gottenberg JE, Ravaud P, Bardin T et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.
51. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53-61.
52. Ortún Rubio V. ¿Quédebería saber un clínico de Economía? [What should a doctor know about economy?] In: Millan Núñez-Cortes J, del Llano Señarís JE, eds. Ser médico Los valores de una profesión [Being a doctor: The values of a profession]. Alcobendas, Madrid (Spain): Unión Editorial, SA, 2012.
53. den Broeder A, van de Putte L, Rau R et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29: 2288-98.
54. European Medicines Agency. Assessment Report For Mabthera (rituximab): Procedure No.: EMEA/H/C/000165/ II/0065. London: EMA, 2010.
55. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 2010;50:754-66.
56. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-4.
57. Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30:1426-35.
58. St Clair EW, Wagner CL, Fasanmade AA et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
59. Sociedad Española de Reumatología. Proyecto EMAR II. Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España. Informe de resultados. Madrid: SER, 2011 [updated February 2011]. http://www. ser.es/ArchivosDESCARGABLES/Proyectos/Emar/ EMAR_Informe.pdf (5 September 2013, date last accessed).
60. Fitch K. The Rand/UCLA appropriateness method user's manual. Santa Monica: Rand, 2001.
61. Scottish Intercollegiate Guidelines Network. A guideline developer's handbook: SIGN 50. Edinburgh: SIGN (NHS Quality Improvement Scotland), 2008. http://www. intute.ac.uk/healthandlifesciences/cgi-bin/fullrecord. pl?handle=20080207-11330481 (28 August 2013, date last accessed).
62. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
63. Saleem B, Keen H, Goeb V et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69: 1636-42.
64. Tanaka Y, Takeuchi T, Mimori T et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69: 1286-91.
65. Smolen JS, Nash P, Durez P et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
66. van der Maas A, Kievit W, van den Bemt BJ et al. Downtitration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71:1849-54.
67. Brocq O, Millasseau E, Albert C et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76: 350-5.
68. Baraliakos X, Listing J, Brandt J et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7: R439-44.
69. Poddubnyy D, Rudwaleit M, Haibel H et al. Effect of nonsteroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616-22.
70. Wanders A, Heijde D, Landewe R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
71. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
72. Sieper J, van der Heijde D, Dougados M et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebocontrolled trial (ABILITY-1). Ann Rheum Dis 2013;72: 815-22.
73. Song IH, Weiss A, Hermann KG et al. Similar response rates in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013;72:823-5.
74. Visvanathan S, Wagner C, Marini JC et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-7.
75. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2005;52: 27-35.
76. van den Broek M, Klarenbeek NB, Dirven L et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
77. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004;31:1103-11.
78. St Clair EW, Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;11:3432-43.
79. Emery P, Fleischmann R, van der Heijde D et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
80. Keystone EC, Combe B, Smolen J et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology 2012;51:1628-38.
81. Kremer JM, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
82. Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
83. Tada M, Koike T, Okano T et al. Comparison of joint destruction between standard-and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. Rheumatology 2012;51:2164-9.
84. Tak PP, Rigby W, Rubbert-Roth A et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 2012;71:351-7.
85. Baraliakos X, Listing J, Rudwaleit M et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
86. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-5.
87. Teng YK, Tekstra J, Breedveld FC et al. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis 2009;68:1075-7.
88. Emery P, Mease PJ, Rubbert-Roth A et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology 2011;50:2223-32.
89. Mariette X, Rouanet S, Sibilia J et al. Evaluation of lowdose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 2014;73:1508-14.
90. van Vollenhoven RF, Emery P, Bingham CO III et al. Longterm safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
91. De La Torre I, Leandro MJ, Valor L et al. Total serum immunoglobulin levels in patients with RA after multiple B cell depletion cycles based on rituximab: relationship with B cell kinetics. Rheumatology 2012;51:833-40.
92. Bredemeier M, de Oliveira FK, Rocha CM. Low-versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 2014;66: 228-35.
93. Vital EM, Rawstron AC, Dass S et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011;63:603-8.
94. Kastbom A, Coster L, Arlestig L et al. Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open 2012;2:e001524.
95. Ruyssen-Witrand A, Rouanet S, Combe B et al. Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2012;71:875-7.
96. Dall'Ozzo S, Tartas S, Paintaud G et al. Rituximabdependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.